Fujita M, Inoue E, Kuroda C, Kasugai H, Sasaki Y, Nakano H, Imaoka S
Dept. of Diagnostic Radiology, Osaka Medical Center for Cancer and Cardiovascular Diseases.
Gan To Kagaku Ryoho. 1998 Feb;25 Suppl 1:105-8.
To evaluate the efficacy and adverse reaction of SMANCS, we reviewed 10 cases treated by TAE with SMANCS among 896 cases treated by TAE for liver cancer during the past three years at our institute. Our criteria for using SMANCS were as follows: a) reduced effectiveness of past TAE with Lipiodol, hydrophilic drugs and gelatin sponge; b) sufficient caliber and blood flow in the hepatic artery; and c) good hepatic function. The 1- and 2-year survival rates after treatment with SMANCS were 50% and 25%, respectively. The 3- and 5-year survival rates after initial treatment (first TAE, etc.) were 40% and 20%, respectively. There were no significant complications in clinical course, however, subsequent hepatic arteriogram often showed arterial change that may interfere with further regional therapy for the liver.
为评估丝裂霉素多柔比星（SMANCS）的疗效及不良反应，我们回顾了我院过去三年896例接受经动脉化疗栓塞（TAE）治疗肝癌患者中，10例接受TAE联合SMANCS治疗的病例。我们使用SMANCS的标准如下：a）既往使用碘油、亲水性药物及明胶海绵行TAE效果不佳；b）肝动脉管径及血流充足；c）肝功能良好。接受SMANCS治疗后的1年及2年生存率分别为50%和25%。初始治疗（首次TAE等）后的3年及5年生存率分别为40%和20%。临床过程中无明显并发症，然而，随后的肝动脉造影常显示动脉改变，这可能会干扰进一步的肝脏区域治疗。
